stockrow
Saturday 7 November 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
- EPS
- −717.0%
- Free cash flow
- +89.0%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
2.50
0.13
−4.94%
Follow LIMN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (4) | (10) | (13) | +187.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (4) | (10) | (13) | +187.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (10.13) | (21.50) | (23.50) | +112.2% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (4.15) | (20.97) | (4.10) | +405.8% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (4.15) | (21.00) | (4.10) | +406.5% | ||||||
| Book value | — | — | — | — | — | — | — | — | (55.26) | (20.66) | 0.31 | (62.6%) | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 0 | 0 | 1 | +35.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (1) | (10) | (4) | +586.6% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (1) | (10) | (4) | +587.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | (19) | (10) | 0 | (49.7%) | |||||
| Net debt | — | — | — | — | — | — | — | — | 20 | 1 | (2) | (94.5%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (19) | (10) | 0 | (49.3%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (344.72) | (471.47) | (344.7) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | (360.95) | 0.00 | 0.00 | +361.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 70.02 | 294.43 | +70.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 1 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Liminatus Pharma Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $3.8M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $3.6M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $3.5M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | |
| GRI GRI Bio, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $3.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| ONCO Onconetix, Inc. | $3.2M | — (loss-making) | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| Median of peers | $3.4M | — | — | −60.19% | — | −7.76% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 13 July 2026
Ownership
Directors and executive officers, together
19.40%
Chris Kim
14.30%
Valetudo Therapeutics LLC
14.30%
Ewon Comfortech Co., Ltd.
8.20%
Beom K. Choi
5.10%
Samda Biolab Co., Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . .
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement